Table 2 Population pharmacokinetic parameters of terlipressin and L-VP in patients with HRS (final PK model)
From: Pharmacokinetic and pharmacodynamic analyses of terlipressin in patients with hepatorenal syndrome
Parameters | Estimate (RSE%)a | 95% CIb |
|---|---|---|
CLA (L/h) | 27.4 (8.7) | 24.8–31.1 |
WT on CLAc | 0.549 (36.2) | 0.413–0.850 |
V1A (L) | 6.31 (23.3) | 4.87–9.33 |
QAd (L/h) | 35.6 (16.7) | 24.0–43.1 |
V2Ad (L) | 18.4 (8.6) | 15.6–22.1 |
CLM/Fm (L/h) | 318 (11.5) | 283–363 |
VM/Fm (L) | 1370 (18.8) | 1190–1520 |
BSV of CLA (CV%) | 34.8 (39.4) | 24.7–50.3 |
BSV of V1A (CV%) | 61.9 (121.9) | 35.5–113.1 |
BSV of CLM/Fm (CV%) | 65.8 (33.5) | 54.2–73.1 |
BSV of VM/Fm (CV%) | 67.7 (34.9) | 53.3–81.9 |
Residual errors (CV%) | ||
Terlipressin—study 1 | 70.0 (14.1) | 59.5–76.2 |
L-VP—study 1 | 47.2 (5.6) | 37.1–59.4 |
Terlipressin—study 2 | 39.7 (6.5) | 28.2–51.6 |
L-VP—study 2 | 26.9 (18.4) | 20.9–30.3 |